MARKET

SRDX

SRDX

Surmodics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.35
+0.45
+1.16%
After Hours: 39.35 0 0.00% 16:02 05/27 EDT
OPEN
40.12
PREV CLOSE
38.90
HIGH
40.21
LOW
39.17
VOLUME
20.15K
TURNOVER
0
52 WEEK HIGH
62.27
52 WEEK LOW
32.43
MARKET CAP
550.51M
P/E (TTM)
-52.1607
1D
5D
1M
3M
1Y
5Y
Looking Into Surmodics's Return On Capital Employed
Surmodics (NASDAQ:SRDX) brought in sales totaling $26.11 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 45.2%, resulting in a loss of $4.08 million.
Benzinga · 05/02 13:52
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Zacks · 04/29 16:18
Needham Adjusts SurModics' Price Target to $46 From $58; Buy Rating Kept
MT Newswires · 04/28 05:41
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/27 12:45
Recap: Surmodics Q2 Earnings
  Surmodics (NASDAQ:SRDX) reported its Q2 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 04/27 11:49
Surmodics Q2 EPS $(0.22) Beats $(0.34) Estimate, Sales $26.10M Beat $23.97M Estimate
Surmodics (NASDAQ:SRDX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.34) by 35.29 percent. This is a 135.48 percent decrease over earnings of $0.62 per share from the
Benzinga · 04/27 11:34
BRIEF-Surmodics Reports Q2 Fiscal 2022 Results
reuters.com · 04/27 11:34
BRIEF-Pounce Thrombectomy System First-In-Human Data Show 100% Technical Success In Early Cases
reuters.com · 04/27 11:24
More
No Data
Learn about the latest financial forecast of SRDX. Analyze the recent business situations of Surmodics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRDX stock price target is 74.00 with a high estimate of 114.00 and a low estimate of 46.00.
High114.00
Average74.00
Low46.00
Current 39.35
EPS
Actual
Estimate
-0.30-0.23-0.15-0.08
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 197
Institutional Holdings: 13.20M
% Owned: 94.34%
Shares Outstanding: 13.99M
TypeInstitutionsShares
Increased
40
528.77K
New
8
125.21K
Decreased
55
450.18K
Sold Out
20
84.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.86%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Non-Executive Chairman/Independent Director
Susan Knight
Chief Executive Officer/President/Director
Gary Maharaj
Chief Financial Officer/Senior Vice President - Finance
Timothy Arens
Senior Vice President/Chief Marketing Officer
Teri Sides
Senior Vice President/General Counsel/Secretary
Gordon Weber
Senior Vice President/General Manager
Joseph Stich
Senior Vice President
Charles Olson
Vice President
Nusrath Sultana
Independent Director
Jose Bedoya
Independent Director
David Dantzker
Independent Director
Lisa Heine
Independent Director
Ronald Kalich
No Data
No Data
About SRDX
Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Webull offers kinds of SurModics, Inc. stock information, including NASDAQ:SRDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRDX stock methods without spending real money on the virtual paper trading platform.